机译:Endostar和贝伐单抗联合培美曲塞/顺铂胸腔内注射治疗表皮生长因子受体/间变性淋巴瘤激酶-肺腺癌患者恶性胸腔积液的比较
[1]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;
[2]Allergy Department,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology, Wuhan 430030,China;
[1]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;
[1]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;
[1]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;
[1]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;
[1]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;
[1]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;
Endostar; bevacizumab; malignant pleural effusion; EGFR-/ALK-lung adenocarcinoma; cisplatin; pemetrexed; intra-pleural injection;